Intestinal Cells-based In Vitro Screening Service
Unleashing Cell Power, Advancing Your Research
Digestion and absorption of carbohydrates occur primarily in the small intestine, where the breakdown of oligosaccharides and disaccharides tends to take place. The intestinal epithelium is the fastest-renewing tissue in humans, containing multiple cell types and a dynamic, multi-parameter microenvironment. Intestinal cells play a key role in the regulation of nutrient metabolism and energy balance and are a critical part of the regulation of intestinal sugar transport. Moreover, intestinal cell models accurately mimic human physiology, creating well-controlled and reproducible conditions for assessing cellular responses.
High-quality Intestinal Cells-based In Vitro Screening Service at CD BioGlyco
CD BioGlyco has long been committed to the development of Glycobiology Disease Models and has accumulated extensive experience in the field of In Vitro Glycobiology Disease Model Screening. Here, we provide our clients with a comprehensive and high-quality intestinal cells-based in vitro screening service.
- Establishing intestinal cell models
We incubate the intestinal cells by placing them in a medium modified with monosaccharides, to which we add specific growth factors as well as amino acids. At the same time, we change the medium at determined intervals so that the intestinal cells divide in a certain ratio.
For example, CaCo-2/TC7 cells are placed for growth in Eagle medium modified with D-glucose, which contains compounds such as penicillin, non-essential amino acids, and L-glutamine. This allowed the CaCo-2/TC7 cells to divide at a ratio of 1:20 and be used for subsequent experiments.
- Screening of intestinal cells
The intestinal cells obtained from the culture are continued to be placed in a mixture of glycans for incubation, and we test the accumulation of glycans in the intestinal cells at different incubation times. To determine the specific accumulation of glycans, we test the intestinal cells using reverse transcription-polymerase chain reaction (RT-PCR) and detect the presence of expression of glycan-related genes in the cells.
In addition, to adequately perform glycan screening, we make changes to the culture medium, mix the concentration of glycans and external conditions such as incubation time, and test the uptake and screening of glycans by intestinal cells.
![Process of our intestinal cells-based in vitro screening service. (CD BioGlyco)](https://www.bioglyco.com/wp-content/themes/glycobio/img/4-16-5-6-intestinal-cells-based-in-vitro-screening-service-1.jpg)
- Our intestinal cell models offered to our clients herein include, but are not limited to, the following.
- Caco-2 cell model
The Caco-2 cell line, derived from human colorectal adenocarcinoma, is a mature in vitro model of human intestinal epithelial cells capable of absorbing and ingesting monosaccharides such as glucose, fructose, etc. CD BioGlyco provides clients with a mature Caco-2 cell model, as well as professional in vitro screening services based on the Caco-2 cell model.
- HT-29 cell model
The ability of HT-29 cells to express the properties of mature intestinal cells makes them an effective model for current research on the fundamental mechanisms controlling intestinal homeostasis and pathology, as well as for in vitro screening of glycobiology diseases. CD BioGlyco provides custom HT-29 cell model services with rich experience in the in vitro screening of glycobiology disease models.
- Rat intestinal epithelial cells IEC-6 model
IEC-6 is a cell line that exhibits epithelial morphology and can be affected by astragalus polysaccharides (APS) for proliferation, migration, and differentiation. CD BioGlyco utilizes scanning electron microscopy to assay the effects of polysaccharides on IEC-6 cell differentiation. We utilize the IEC-6 model to provide high-quality glycobiology disease screening services to our clients.
- 3D intestinal epithelial cells model
This cell line is a three-dimensional level cell model that accurately mimics human physiology, creating well-controlled and reproducible conditions for evaluating cellular uptake and translocation of glycans. CD BioGlyco combines multidisciplinary skills, to provide in vitro screening of glycobiology diseases based on the 3D intestinal epithelial cells model to clients.
Publication Data
Technology: CaCo-2 cell model, RT-PCR
Journal: PLOS ONE
IF: 3.7
Published: 2016
Results: The authors evaluated the effects of sugar and artificial sweeteners on small intestinal sugar transport using intestinal CaCo-2 cells as a model of intestinal sugar transport. First, in the presence and absence of the sweet taste receptor inhibitor lactitol, the authors preincubated CaCo-2 cells with sugar and artificial sweeteners, respectively, for a short time and assessed the uptake of D-glucose and D-fructose by CaCo-2 cells. Next, the authors determined the expression of intestinal sugar transporter proteins and sweet taste receptors using RT-PCR. The results showed that in the short term, enterocyte sugar transport activity responds directly to extracellular glucose levels, but not to fructose or artificial sweeteners. However, when glucose and fructose were administered together, there was an inhibitory effect on glucose transport possibly mediated by T1R3.
Fig.1 Time course of D-glucose, D-fructose, and L-glucose uptake into Caco-2/TC7 cells. (O'Brien & Corpe, 2016)
Applications
- The in vitro screening service based on intestinal cells can be used to investigate the physiological functions of intestinal cells in the human body, such as glycan transporter, and glycan catabolism.
- Intestinal cell-based in vitro screening services can be used to research the function of the gastrointestinal tract, and the insulin release process in the human body.
- Intestinal cell-based in vitro screening services can be used for high-throughput drug screening to assess the intestinal permeability of drugs.
Advantages
- Our in vitro intestinal cell screening service can perform a large number of glycan screening experiments at the same time, dramatically improving research efficiency.
- We provide intestinal cells in vitro screening one-stop service, which involves modeling, high throughput screening of glycans, cell level screening, selective testing, etc.
- We have advanced biological technology and custom intestinal cell models for glycobiology diseases according to specific research needs, such as testing conditions, cell types, etc.
CD BioGlyco has long been committed to the development of glycobiological disease models based on specialized biology and genetics. Our glycobiology disease models have won high praise both in vivo and in vitro from our clients. Please feel free to contact us if you are interested in our intestinal cell models or if you have any questions.
Reference
- O'Brien, P.; Corpe, C.P. Acute effects of sugars and artificial sweeteners on small intestinal sugar transport: a study using CaCo-2 cells as an in vitro model of the human enterocyte. PLOS ONE. 2016, 12(10): e0186016.
This service is for Research Use Only, not intended for any clinical use.